Table 2 Overall response rate on target areas (A) and best overall response (B – detailed response and C – CR + PR and SD + PD) for the standard dosimetry group at 3 and 6 months, according to mRECIST
(A) mRECIST ORR for HCC treated nodules | ||||
|---|---|---|---|---|
3 months | 6 months | |||
Group A N = 19 | Group B N = 16 | Group A N = 10 | Group B N = 9 | |
Response (n, %) | ||||
CR | 2/19 (10.53%) | 5/16 (31.25%) | 1/10 (10%) | 3/9 (33.33%) |
PR | 11/19 (57.89%) | 9/16 (56.25%) | 4/10 (40%) | 5/9 (55.56%) |
SD | 3/19 (15.79%) | 1/16 (6.25%) | 1/10 (10%) | 0/9 (0%) |
PD | 3/19 (15.79%) | 1/16 (6.25%) | 4/10 (40%) | 1/9 (11.11%) |
mRECIST ORR for HCC treated nodules | |||
|---|---|---|---|
Group A N = 19 | Group B N = 16 | p-value | |
Response 3 months: n (%) | 0.24 | ||
CR + PR | 13 (68.4%) | 14 (87.5%) | |
SD + PD | 6 (31.6%) | 2 (12.5%) | |
DCR (CR + PR + SD) 3 months: n (%) | 16 (84.2%) | 15 (93.8%) | 0.61 |
Group A N = 10 | Group B N = 9 | p-value | |
|---|---|---|---|
Response 6 months: n (%) | 0.14 | ||
CR + PR | 5 (50.0%) | 8 (88.9%) | |
SD + PD | 5 (50.0%) | 1 (11.1%) | |
(B) BOR according to mRECIST overall | ||||
|---|---|---|---|---|
3 months | 6 months | |||
Group A N = 18 | Group B N = 15 | Group A N = 9 | Group B N = 9 | |
Response (n, %) | ||||
CR | 1/18 (5.56%) | 5/15 (33.33%) | 1/9 (11.11%) | 3/9 (33.33%) |
PR | 5/18 (27.78%) | 7/15 (46.67%) | 1/9 (11.11%) | 4/9 (44.44%) |
SD | 5/18 (27.78%) | 1/15 (6.67%) | 1/9 (11.11%) | 0/9 (0%) |
PD | 7/18 (38.89%) | 2/15 (13.33%) | 6/9 (66.67%) | 2/9 (22.22%) |
BOR according to mRECIST/overall | |||
|---|---|---|---|
Group A N = 18 | Group B N = 15 | p-value | |
Response 3 months: n (%) | 0.007 | ||
CR + PR | 6 (33.3%) | 12 (80.0%) | |
SD + PD | 12 (66.7%) | 3 (20.0%) | |
Group A N = 9 | Group B N = 9 | p-value | |
|---|---|---|---|
Response 6 months: n (%) | 0.06 | ||
CR + PR | 2 (22.2%) | 7 (77.8%) | |
SD + PD | 7 (77.8%) | 2 (22.2%) | |